Press Releases

Publication of shareholders’ letter // DANISH TRANSLATION: Offentliggørelse af nyhedsbrev til aktionærerne

Paris (France), Copenhagen (Denmark)– Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announces the publication of its 8th Shareholders Letter. This latest Shareholders Letter provides an update on Onxeo’s major achievements in 2015 with a focus on the positive results of the Phase I clinical trial of Bel-CHOP (association…read more →

Onxeo announces its financial calendar for 2016 // DANISH TRANSLATION: Onxeo offentliggør selskabets finanskalendar for 2016

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announces its financial calendar for 2016: February 26, 2016                               Full-year 2015 results  April 6, 2016                                         General shareholders’ meeting (to be convened in Paris) April 28, 2016                                      Quarterly information as of March 31, 2016 July…read more →

Spectrum Pharmaceuticals and Onxeo announce complete response in 67% of patients with peripheral T-cell lymphoma in combination of belinostat (Beleodaq®) and standard CHOP // DANISH TRANSLATION: Onxeo og Spectrum Pharmaceuticals offentliggør, at der er opnået komplet respons hos 67 % af patienterne med perifert T-celle lymfekræft (PTCL) med kombinationen af belinostat (Beleodaq®) og standard CHOP-behandling

Data was Highlighted in an Oral Presentation of a Phase 1 Study at the 57th Annual Meeting of the American Society of Hematology (ASH) Study Shows 86% Objective Response Rate with 67% Complete Responses in Newly Diagnosed Patients with Peripheral T-cell Lymphoma (PTCL) At Full Dose Intensity the Belinostat-CHOP Combination was Well-Tolerated HENDERSON, Nev. and PARIS (France), COPENHAGEN (Denmark) –…read more →

Onxeo initiates comprehensive strategy to extend value of key orphan oncology assets // DANISH TRANSLATION: Onxeo indleder omfattende strategiplan for at øge værdien af selskabets vigtigste lægemidler til behandling af sjældne kræftsygdomme

Currently exploring combinations for synergistic effect to identify new indications for Livatag® and Beleodaq® Signed two collaborations with Lyon’s University Hospital and Synovo’s immuno-oncology specialists  Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, announced the initiation of a comprehensive strategy to explore further potential indications…read more →

Onxeo Reports Initial Results of Phase 1 Trial Evaluating Belinostat in Combination with CHOP in Peripheral T-cell Lymphoma (PTCL) — Onxeo rapporterer foreløbige resultater fra fase I-studiet til evaluering af belinostat i kombination med CHOP-behandling mod perifert T-celle lymfekræft (PTCL)

Full results to be reported in Oral Presentation at 2015 ASH (American Society of Hematology) Annual Meeting Data demonstrate 89% objective response rate, 72% complete response rate, and good safety profile of belinostat in combination with CHOP Study supports the interest of belinostat in combination with CHOP as first-line treatment for PTCL Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext…read more →

Onxeo to attend upcoming investor events — Onxeo deltager i kommende investormøder

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announces its participation to financial conferences in the coming months. During these conferences, Onxeo’s management will present the recent achievements and the growth strategy of the Company to institutional and individual investors. Meetings with institutional investors:…read more →

Onxeo Announces Data Demonstrating High Patient Compliance and Acceptability of Validive® for Treatment of Severe Oral Mucositis — Onxeo offentliggør data, der viser et højt niveau af ordinationsoverholdelse og en god sikkerhedsprofil for Validive® til behandling af svær oral mucositis

Results Presented in Oral ePoster Presentation at ASTRO Annual Meeting 2015 Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, announced compliance and patient acceptability results from a global Phase 2 clinical trial demonstrating daily treatment application of Validive® (Clonidine Lauriad®), a mucoadhesive buccal tablet for…read more →

Onxeo Validive® Abstract Accepted for Oral Presentation at ASTRO Annual Meeting 2015 — Abstract for Onxeo Validive® accepteret til mundtlig præsentation ved ASTRO’s årsmøde 2015

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced that an abstract supporting the clinical evaluation of Validive® (Clonidine Lauriad®), a mucoadhesive buccal tablet developed for the prevention and treatment of chemo-radioation therapy-induced severe oral mucositis (SOM) in patients with head and neck cancer,…read more →

Onxeo announces evolution in the Board of Directors — Onxeo offentliggør ændring i bestyrelsen

Mr. Patrick Langlois is planning to step down from the chairmanship in early 2016 for personal reasons Mr. Joseph Zakrzewski is joining the Board and is expected to be appointed Non-Executive Chairman in 2016 Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative biopharmaceutical company specializing in the development of orphan oncology drugs, today announced…read more →

Onxeo announces positive DSMB recommendation for continuation of Livatag® ReLive study in HCC — Onxeo offentliggør positiv anbefaling fra DSMB om at fortsætte ReLive-studiet med Livatag® mod leverkræft

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced that it has received a unanimous recommendation from the Data Safety Monitoring Board (DSMB), the independent European board of experts that monitors the safety of the Livatag® Phase III trial, “ReLive”, to continue the study…read more →

Publication of a new letter to shareholders — Offentliggørelse af nyt aktionærbrev

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announces the publication of its new letter to shareholders. This issue is devoted to our orphan oncology product Beleodaq®. You will find full information about the product, its key features and indications, as well as interviews…read more →

Decision in the litigation opposing Onxeo to the companies Eurofins and ABL – Afgørelse i retssagen mod Eurofins og ABL

Decision in the litigation opposing Onxeo to the companies Eurofins and ABL Recognition of  Eurofins’s debt to Onxeo resulting from the absence of payment of the option This debt is compensated by damages benefiting Eurofins None of the parties obliged to the payment of has to pay an indemnity towards the other Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an…read more →

Corporate Governance prize awarded by AGEFI: Onxeo receives “Silver Governance” for the second consecutive year

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative biopharmaceutical company specialized in the development of orphan oncology drugs, has been awarded for the second consecutive year the “Silver Governance” in the small and midcap companies category at the Twelfth Annual Corporate Governance Awards held by the French financial magazine AGEFI on September 16, 2015. The Corporate Governance Prizes reward…read more →

Onxeo files application for key Livatag® patent — Onxeo indleverer ansøgning om vigtigt patent for Livatag®

Potential expansion of Livatag IP estate to extend commercial exclusivity through 2036 Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative biopharmaceutical company specialized in the development of drugs for orphan oncology diseases, today announced that it has filed an international patent application to protect the overall compound related to its primary liver cancer orphan oncology product Livatag®. The patent…read more →